会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Inhibition of wet type age related macular degeneration (AMD) by adiponectin or acrp 30
    • 通过脂联素或acrp抑制湿型年龄相关性黄斑变性(AMD)30
    • US07964557B2
    • 2011-06-21
    • US11910188
    • 2006-03-22
    • Puran S. BoraNalini S. BoraHenry J. Kaplan
    • Puran S. BoraNalini S. BoraHenry J. Kaplan
    • A61K38/00A61K47/00A61K49/00A61P27/02C07K7/00
    • A61K38/2264
    • The present invention provides new methods of treating wet type of age related macular degeneration by administering adiponectin (APN) or a functional fragment derived therefrom. One of the pathological complications of age related macular degeneration (AMD) is choroidal angiogenesis or choroidal neovascularization (CNV). The inventors discovered that the level of APN expression is significantly lower in the choroids of the laser-induced mouse model of choroidal angiogenesis or choroidal neovascularization (CNV) than that of the control mice and that administration of recombinant adiponectin (rAPN) or a peptide derived from the globular domain of the intact APN protein to the mouse model of CNV reduced the size of CNV significantly. These studies are the first to demonstrate the inhibitory effect of adiponectin on choroidal angiogenesis and thus provide the basis for treating a condition or disease involving angiogenesis, particularly age related macular degeneration, with administration of adiponectin.
    • 本发明提供了通过施用脂联素(APN)或其衍生的功能片段治疗湿性年龄相关性黄斑变性的新方法。 年龄相关性黄斑变性(AMD)的病理并发症之一是脉络膜血管生成或脉络膜新生血管形成(CNV)。 发明人发现激光诱导的脉络膜血管生成或脉络膜新血管形成(CNV)小鼠模型的脉络膜的APN表达水平明显低于对照小鼠,并且施用重组脂联素(rAPN)或肽衍生物 从完整的APN蛋白的球状结构域到CNV的小鼠模型显着降低CNV的大小。 这些研究首先证明脂联素对脉络膜血管生成的抑制作用,从而提供了通过给予脂联素治疗涉及血管发生,特别是年龄相关性黄斑变性的病症或疾病的基础。
    • 4. 发明授权
    • Methods and compositions for modulating ocular damage
    • 用于调节眼部损伤的方法和组合物
    • US09155790B2
    • 2015-10-13
    • US13698518
    • 2011-05-20
    • Tongalp H. TezelHenry J. KaplanRobert A. MitchellJohn O. Trent
    • Tongalp H. TezelHenry J. KaplanRobert A. MitchellJohn O. Trent
    • A61K31/517A61K39/395A61K31/505A61K31/53A61K45/06
    • A61K39/3955A61K31/505A61K31/53A61K45/06A61K2300/00
    • Methods for modulating eye damage associated with a disease or disorder, and/or damage incident to trauma including but not limited to trauma associated with ocular surgery are provided. In some embodiments, the methods include administering an effective amount of a modulator of a migration inhibitory factor (MIF) polypeptide biological activity to a subject. Also provided are methods for modulating the severity of delaying the onset of and/or inhibiting and/or preventing the development of an ocular disease, and methods for modulating the severity of delaying the onset of and/or inhibiting and/or preventing the development of scarring and/or other consequence of wound healing incident to ocular surgery, as well as modulating the survival, function, and/or differentiation of engrafted cells that can be employed as part of tissue engineering procedures to correct structural, functional, and/or cellular defects of the eye.
    • 提供了用于调节与疾病或病症相关的眼睛损伤和/或损伤事件的方法,包括但不限于与眼部手术相关的创伤。 在一些实施方案中,所述方法包括向受试者施用有效量的迁移抑制因子(MIF)多肽生物活性的调节剂。 还提供了用于调节延缓发作和/或预防眼部疾病发展的严重性的方法,以及调节延缓发作和/或抑制和/或预防眼部疾病的发生的严重性的方法 伤口愈合和/或眼部手术引起的伤口愈合的其他结果,以及调节可以用作组织工程程序的一部分以修正结构,功能和/或细胞的移植细胞的存活,功能和/或分化 眼睛的缺陷。
    • 7. 发明申请
    • Inhibition of Wet Type Age Related Macular Degeneration (Amd) by Adiponectin or Acrp 30
    • 脂联素或Acrp抑制湿型年龄相关性黄斑变性(Amd)30
    • US20080221030A1
    • 2008-09-11
    • US11910188
    • 2006-03-22
    • Puran S. BoraNalini S. BoraHenry J. Kaplan
    • Puran S. BoraNalini S. BoraHenry J. Kaplan
    • A61K38/17C12N5/06A61K38/10A61P27/02
    • A61K38/2264
    • The present invention provides new methods of treating wet type of age related macular degeneration by administering adiponectin (APN) or a functional fragment derived therefrom. One of the pathological complications of age related macular degeneration (AMD) is choroidal angiogenesis or choroidal neovascularization (CNV). The inventors discovered that the level of APN expression is significantly lower in the choroids of the laser-induced mouse model of choroidal angiogenesis or choroidal neovascularization (CNV) than that of the control mice and that administration of recombinant adiponectin (rAPN) or a peptide derived from the globular domain of the intact APN protein to the mouse model of CNV reduced the size of CNV significantly. These studies are the first to demonstrate the inhibitory effect of adiponectin on choroidal angiogenesis and thus provide the basis for treating a condition or disease involving angiogenesis, particularly age related macular degeneration, with administration of adiponectin.
    • 本发明提供了通过施用脂联素(APN)或其衍生的功能片段治疗湿性年龄相关性黄斑变性的新方法。 年龄相关性黄斑变性(AMD)的病理并发症之一是脉络膜血管生成或脉络膜新生血管形成(CNV)。 发明人发现激光诱导的脉络膜血管生成或脉络膜新血管形成(CNV)小鼠模型的脉络膜的APN表达水平明显低于对照小鼠,并且施用重组脂联素(rAPN)或肽衍生物 从完整的APN蛋白的球状结构域到CNV的小鼠模型显着降低CNV的大小。 这些研究首先证明脂联素对脉络膜血管生成的抑制作用,从而提供了通过给予脂联素治疗涉及血管发生,特别是年龄相关性黄斑变性的病症或疾病的基础。
    • 8. 发明授权
    • Subretinal implantation device and surgical cannulas for use therewith
    • 视网膜下植入装置和与其一起使用的外科插管
    • US07189245B2
    • 2007-03-13
    • US10367353
    • 2003-02-14
    • Henry J. Kaplan
    • Henry J. Kaplan
    • A61F9/00
    • A61F9/007A61F9/00727A61F9/08
    • An implantation device having a reservoir for holding a solid or semisolid implant and a carrier fluid, wherein the reservoir includes a cannula. The cannula has a tip end and a delivery opening therein both shaped and dimensioned to suit the application. For example, an implant (such as a retinal cell graft) and suitable carrier fluid (such as an aqueous hyaluronic acid solution) can be expressed from the opening into the subretinal space of a recipient eye, provided the cannula is of sufficient length that the tip end can reach the subretinal space while the remainder of the fluid reservoir is external of the eye. Expression of the carrier fluid from the reservoir via the delivery opening expels the implant through the delivery opening. An electromechanically driven plunger apparatus with operator controls is provided in a preferred embodiment.
    • 一种具有用于保持固体或半固体植入物和载体流体的储存器的植入装置,其中所述储存器包括套管。 插管具有尖端和其中的输送开口,其形状和尺寸适于适用。 例如,植入物(例如视网膜细胞移植物)和合适的载体流体(例如水性透明质酸溶液)可以从开口进入受体眼的视网膜下空间,只要插管具有足够的长度, 尖端可以到达视网膜下空间,而液体储存器的其余部分在眼睛外部。 载体流体经由输送口从储存器的表达通过输送口排出植入物。 在优选实施例中提供具有操作员控制的机电驱动的柱塞装置。
    • 9. 发明申请
    • METHODS AND COMPOSITIONS FOR MODULATING OCULAR DAMAGE
    • 调节眼损伤的方法和组合物
    • US20130177552A1
    • 2013-07-11
    • US13698518
    • 2011-05-20
    • Tongalp H. TezelHenry J. KaplanRobert A. MitchellJohn O. Trent
    • Tongalp H. TezelHenry J. KaplanRobert A. MitchellJohn O. Trent
    • A61K39/395A61K31/505
    • A61K39/3955A61K31/505A61K31/53A61K45/06A61K2300/00
    • Methods for modulating eye damage associated with a disease or disorder, and/or damage incident to trauma including but not limited to trauma associated with ocular surgery are provided. In some embodiments, the methods include administering an effective amount of a modulator of a migration inhibitory factor (MIF) polypeptide biological activity to a subject. Also provided are methods for modulating the severity of delaying the onset of and/or inhibiting and/or preventing the development of an ocular disease, and methods for modulating the severity of delaying the onset of and/or inhibiting and/or preventing the development of scarring and/or other consequence of wound healing incident to ocular surgery, as well as modulating the survival, function, and/or differentiation of engrafted cells that can be employed as part of tissue engineering procedures to correct structural, functional, and/or cellular defects of the eye.
    • 提供了用于调节与疾病或病症相关的眼睛损伤和/或损伤事件的方法,包括但不限于与眼部手术相关的创伤。 在一些实施方案中,所述方法包括向受试者施用有效量的迁移抑制因子(MIF)多肽生物活性的调节剂。 还提供了用于调节延缓发作和/或预防眼部疾病发展的严重性的方法,以及调节延缓发作和/或抑制和/或预防眼部疾病的发生的严重性的方法 伤口愈合和/或眼部手术引起的伤口愈合的其他结果,以及调节可以用作组织工程程序的一部分以修正结构,功能和/或细胞的移植细胞的存活,功能和/或分化 眼睛的缺陷。